Lipoprotein Lp(a) and atherothrombotic disease

Archives of Medical Research

Volumn 31, Issue 4, 2000, Pages 353-359

  de la Peña Díaz, Aurora ^a   Izaguirre Avila, Raúl ^a   Anglés Cano, Eduardo ^b  

^a Departamento de Hematología   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Atherosclerosis; Fibrinolysis; Lipoprotein(a); Thrombosis

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; FIBRIN; ISOPROTEIN; LIPOPROTEIN A; MEMBRANE PROTEIN; PLASMIN; PLASMINOGEN; SERINE PROTEINASE;

AMINO ACID COMPOSITION; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; ENDOTHELIUM CELL; GENETIC POLYMORPHISM; HOMOCYSTINURIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; MONOCYTE; PROTEIN ANALYSIS; PROTEIN BINDING; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

APOLIPOPROTEINS A; ARTERIOSCLEROSIS; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033786289     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(00)00084-9     Document Type: Review

References (105)

1. A new serum type system in man-the Lp system
2. Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen
3. cDNA sequence on human apolipoprotein(a) is homologous to plasminogen
4. Lp(a) Lipoprotein; an overview
5. Lp(a) Lipoprotein in cardiovascular disease
6. Plasma lipoproteins; teaching old dogmas new tricks
7. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator
8. Plasma lipoproteins; teaching old dogmas new tricks
9. Lipoprotein(a); structure, properties and possible involvement in thrombogenesis and atherogenesis
10. A potential basis for the thrombotic risks associated with lipoprotein (a)
11. Apolipoprotein (a) size polymorphism in young adults with ischemic stroke
12. The association between Lp(a) concentrations and angiographically assessed coronary atherosclerosis
13. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
14. Lipoprotein (a) and coronary heart disease; a prospective case-control study in a general population sample of middle aged men
15. LDL cholesterol and other risk factors; results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)
16. Lipoprotein (a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial
17. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study
18. Lp(a) lipoprotein is a major risk factor for cardiovascular disease; pathogenic mechanisms and clinical significance
19. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women
20. Lipoprotein (a) and coronary heart disease risk. A nested case-control study of the Helsinki Heart Study participants
21. A prospective study of lipoprotein (a) and the risk of myocardial infarction
22. Apolipoprotein(a) and plasminogen interactions with fibrin; a study with recombinant apolipoprotein(a) and isolated plasminogen fragments
23. Lipoprotein (a) and apolipoprotein (a) in a New World monkey, the common marmoset (Callithrix jacchus)
24. Lipoprotein (a) is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus)
25. Immunological evidence for the accumulation of lipoprotein (a) in the atherosclerotic lesion of the hyperascorbemic guinea pig
26. The physiological role of Lp(a)
27. Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein (a)
28. Molecular biology of lipoprotein(a)
29. Changes of genetic apolipoprotein phenotypes caused by liver transplantation
30. Metabolism of Lp(a); assembly and excretion
31. Lipoproteine, hypofibrinolyse et atherothrombose, quo vadis?
32. Lipoproteina (a) y trombosis
33. A novel kringle 4 number-based recombinant apo(a) standard for human apo(a) phenotyping
34. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis
35. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for non common inulli allele at the apo(a) locus
36. Lp(a) glycoprotein phenotypes; inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
37. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells
38. Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a)
39. Hormonal regulation of serum Lp(a) levels
40. Hormonal agents used in lowering lipoprotein (a)
41. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens
42. Reduction on lecithin-cholesterol actyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazol
43. Growth hormone treatment of growth hormone-deficient adults result in a marked increase in Lp(a) and HDL cholesterol concentrations
44. Lp(a) and the fibrinolytic system
45. Lp(a); an acute phase reactant?
46. Indications of an autoimmune component in Lp(a) associated disorders
47. Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction
48. Differences in apolipoprotein (a) polymorphism in West Greenland Eskimos and Caucasian Danes
49. Lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in Caucasians and African Americans. The CARDIA study
50. Lipoprotein (a) phenotyping using a computerized micro scale and phenotype frequencies in a healthy Japanese population
51. Significant impact of the +93 C/T polymorphism in the apolipoprotein (a) gene on Lp(a) concentrations in Africans but not in Caucasians; confounding effect of linkage
52. Serum LP(a) levels in African aboriginal pygmies and Bantus, compared with Caucasian and Asian population samples
53. The apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans
54. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white American
55. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The artleriosclerosis risk in communities (ARIC) study
56. Proposed mechanisms for binding of apo(a) kringle type 9 to apo B-100 in human lipoprotein(a)
57. Subunit composition of lipoprotein (a) protein
58. Sulfhydryl-selective fluorescence labeling of lipoprotein (a) reveals evidence for one single disulfide linkage between apoprotein(a) and B-100
59. Structural domains of apolipoprotein(a) and its interaction with apolipoprotein B-100 in the lipoprotein(a) particle
60. Subunit composition of lipoprotein(a) protein
61. Expressed hypervariable polymorphism of apolipoprotein (a)
62. A structural assessment of the apo(a) protein of human lipoprotein(a)
63. Physicochemical properties of apolipoprotein (a) and Lp(a-) derived from the dissociation of human plasma Lp(a)
64. Plasma lipoprotein(a) and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region
65. Detection of polymorphisms in the 5'-flanking region of the gene for apo(a)
66. Location of the intermediate and high affinity ω-aminocarboxylic acid binding sites in human plasminogen
67. The role of lipoprotein(a) in atherogenesis and thrombosis
68. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen
69. Lysine/fibrin binding sites of kringles modeled after the structure of kringle 1 of prothrombin
70. The lysine-binding function of Lp(a)
71. Ligand specificity of human plasminogen kringle 4
72. Comparison of ligand binding sites of modeled apo(a) kringle like sequences in human lipoprotein (a)
73. Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells
74. Physiology and pathophysiology of the fibrinolytic system
75. Overview on fibrinolysis; plasminogen activation pathways on fibrin and cell surfaces
76. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
77. Demonstration of covalent binding of lipoprotein (a), [Lp(a)] to fibrin and endothelial cells
78. Physicochemical properties of apolipoprotein (a) and Lp(a-) derived from the dissociation of human plasma Lp(a)
79. Multiple binding with identical linkage; a mechanism that explains the effect of lipoprotein (a) on fibrinolysis
80. Does apolipoprotein (a) heterogeneity influence lipoprotein (a) effects on fibrinolysis?
81. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells
82. Interaction of Lp(a) with plasminogen binding sites on cells
83. Further characterization of the cellular plasminogen binding site; evidence that plasminogen 2 and lipoprotein (a) compete for the same site
84. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation
85. Interaction of lipoprotein (a) with the extracellular matrix
86. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells
87. Lipoprotein(a), plasmin modulation, and atherogenesis
88. Expression of adhesion molecules by Lp(a); a potential novel mechanism for its atherogenicity
89. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin, a study with individual plasmas presenting natural variations of Lp(a)
90. Relevance of lipoprotein (a) in cardiovascular disease; methodological approaches
91. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface
92. Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study
93. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators
94. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu
95. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein (a) isoforms and their affinity for fibrin
96. Homocysteine, atherogenesis and thrombosis
97. Kringle-dependent structural and functional polymorphism of apolipoprotein (a)
98. Lipoprotein(a) reduction by N-acetylcysteine